ReviewBritish journal of pharmacology2002
P2 receptors: new potential players in atherosclerosis.
Review in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 133 citations in OpenAlex.
- Extracellular purines in lung endothelial permeability and pulmonary diseases.Frontiers in physiology · 2024Review
- Genetic polymorphisms of purinergic P2YPurinergic signalling · 2023Article
- P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- ADP exerts P2YJournal of cell communication and signaling · 2020Article
- Association of G-protein coupled purinergic receptor P2Y2 with ischemic stroke in a Han Chinese population of North China.Neural regeneration research · 2019Article
- Be Aware of Aggregators in the Search for Potential HumanMolecules (Basel, Switzerland) · 2018Article
- The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases.Journal of immunology research · 2018Review
- P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels.Scientific reports · 2017Article
- P2XAging and disease · 2017Article
- Deletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty streak formation.Vascular pharmacology · 2016Article
- Short- and long-term (trophic) purinergic signalling.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2016Review
- Purinergic P2Y2 Receptor Control of Tissue Factor Transcription in Human Coronary Artery Endothelial Cells: NEW AP-1 TRANSCRIPTION FACTOR SITE AND NEGATIVE REGULATOR.The Journal of biological chemistry · 2016Article
- A Metabolomic Approach to Understanding the Metabolic Link between Obesity and Diabetes.Molecules and cells · 2015Review
- The Impact of Vitamin D3 Supplementation on Mechanisms of Cell Calcium Signaling in Chronic Kidney Disease.BioMed research international · 2015Article
- The ATP Receptors P2X7 and P2X4 Modulate High Glucose and Palmitate-Induced Inflammatory Responses in Endothelial Cells.PloS one · 2015Article
- P2X receptors regulate adenosine diphosphate release from hepatic cells.Purinergic signalling · 2014Article
- Purinergic receptors and nucleotide processing ectoenzymes: Their roles in regulating mesenchymal stem cell functions.World journal of stem cells · 2014Review
- Article
- Review
- CD39 and CD73 in immunity and inflammation.Trends in molecular medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a focal inflammatory disease of the arterial wall. It starts with the formation of fatty streaks on the arterial wall that evolve to form a raised plaque made of smooth muscle cells (SMCs), and infiltrating leukocytes surrounding a necrotic core. The pathogenesis of the atherosclerotic lesion is incompletely understood, but it is clear that a dysfunction of the endothelium, recruitment and activation of inflammatory cells and SMC proliferation have a pivotal role. Over recent years receptors for extracellular nucleotides, the P2 receptors, have been recognized as fundamental modulators of leukocytes, platelets, SMCs and endothelial cells. P2 receptors mediate chemotaxis, cytokine secretion, NO generation, platelet aggregation and cell proliferation in response to accumulation of nucleotides into the extracellular milieu. Clinical trials have shown the benefit of antagonists of the ADP platelet receptor(s) in the prevention of vascular accidents in patients with atherosclerosis. Therefore, we anticipate that a deeper understanding of the involvement of P2 receptors in atheroma formation will open new avenues for drug design and therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.